FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia

FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia

Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news